| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
NDA Submission example | NDA | — | Subscribe to access the data. | Small Molecules | Nervous System | ||
NDA Submission example | NDA | — | Subscribe to access the data. | Small Molecules | Nervous System | ||
NDA Submission example | NDA | — | Subscribe to access the data. | Small Molecules | Nervous System |
Recent Updates
Recently added Catalysts
Teva Pharmaceutical Industries Limited$32.95
-0.1 (-0.3%)
A 80Pipeline Score Undervalued Generics · Commercial
Market Cap
40.28 B
EPS
1.37
P/E Ratio
25.32 $
Value Trade
165.95 M
SEC Financials
Q1 2026Dilution Risk
Revenue
3.98 B
R&D Expenses
222.00 M
Operating CF
-40.00 M
Total Assets
40.04 B
Total Liabilities
31.81 B
Equity
8.23 B
D/E Ratio
12,345
-2.07 %
Week
8.16 %
1 Month
-0.96 %
3 Month
40.03 %
6 Month
215.46 %
5 Year
5,163.2 %
All Time
Cash Data
Cash Position
3.74 B
Monthly Burn
13.33 M
Runway
278.4 mo
Burn Trend
SEC Filing
Apr 29, 2026
Overview
Volume
6.64 M
52 Week Range
14.99 - 37.35
% held by Insiders
0.01 %
% held by Institutions
62.06 %
Enterprise Value
53.45 B
Total Shares
1.16 B
Short %
2.86 %
Float Shares
1.16 B
Company Description
locked
Upcoming Catalyst
Catalyst Timeline
Dated clinical, regulatory & corporate events for Teva Pharmaceutical Industries Limited
98Total events
0Upcoming
34Tier-1 (high impact)
2016 – 2025Coverage
Event history 98
May 8, 2024
May 8, 2024
▲Primary Endpoint MetClinical Data
Positive Phase 3 efficacy results for olanzapine Once-Monthly LAI
schizophreniasource ↗
2024
◆Timing GuidancePresentation
Initial program results expected in 2024
Ulcerative Colitis and Crohn's Diseasesource ↗
2024
▲Product LaunchNarcanPost-Market
Expansion of generic Narcan shipments expected under nationwide settlement
opioid overdosesource ↗
Nov 17, 2023
Nov 8, 2023
Drug Pipeline Intelligence
A80
Pipeline Score $65.0B
Pipeline ValueUndervalued
Valuation Signal190
Drugs Scored5.4x
rNPV / MCap Top 97%
Mid Cap (rank 28 of 911)
Percentile RankTeva Pharmaceutical Industries Limited earns an A-grade pipeline score (80/100), with $76.5B risk-adjusted pipeline value, led by Reslizumab in Asthma (Phase 3).
Showing 1 of 1 assets
| Drug | Indication | Phase | NCT ID | PTRS | rNPV | Status | Enrollment | Velocity | Design | Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reslizumab Monoclonal antibody | Asthma | Phase 3 | NCT00587288 | 74% | $5.7B | COMPLETED | 761 | - | - | Mar 1, 2010 | - | Aug 17, 2016 |
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 | The study met its primary endpoint demonstrating statistically significant improvement. Read More | Phase 3 Study Results Announcement | |
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 | The study met its primary endpoint demonstrating statistically significant improvement. Read More | Phase 3 Study Results Announcement | |
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 | The study met its primary endpoint demonstrating statistically significant improvement. Read More | Phase 3 Study Results Announcement |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in TEVA
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
TEVA Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
| 2026-08-14 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
| 2026-08-14 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
| 2026-08-14 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
TEVATeva Announces Successful Upsizing and Pricing of $2,300,000,000 (Equivalent) Senior Notes Proceeds to Repay Existing Debt TEL AVIV, Israel (BUSINESS WIRE) Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) ( Teva
Teva Pharmaceutical Industries Ltd. announced the successful upsizing and pricing of approximately $2.3 billion of senior notes aimed at repaying existing debt. The initial offering amount was increased from $2 billion due to strong demand. The funds are expected to be used for tender offers on specific outstanding notes and for other financial obligations. The settlement is projected to occur by May 28, 2025, pending standard closing conditions.
Read more →TEVATEVA ANNOUNCES APPOINTMENT OF MATTHEW SHIELDS TO EXECUTIVE VICE PRESIDENT
Teva Pharmaceutical Industries Ltd. has appointed Matthew Shields as Executive Vice President of Teva Global Operations, effective June 3, 2024. Shields, who has over 25 years of experience in the biopharmaceutical and animal health industries, will succeed Eric Drap, who is leaving after 11 years at the company. Richard Francis, President and CEO, expressed confidence in Shields' ability to lead the operations through Teva's ongoing growth strategy. Shields plans to focus on improving manufacturing processes and delivering on Teva's commitments to patients and healthcare systems globally.
Read more →TEVA▲ +12.8%on this news
For an accessible version of this Press Release, please visit www.tevapharm.com TEVA REPORTS FIRST QUARTER 2024 FINANCIAL RESULTS AND REAFFIRMS 2024 FINANCIAL OUTLOOK Generics business and AUSTEDO growth lead Q1 2024 per
Teva Pharmaceutical Industries Ltd. announced its financial results for Q1 2024, reporting global revenues of $3.8 billion, a 5% increase from Q1 2023. The growth was attributed to success in its generics business and the innovative brands AUSTEDO and AJOVY. The company also highlighted significant advancements in its drug development pipeline, including the FDA approval of two biosimilars. However, Teva experienced an increased operating loss of $218 million, reflecting challenges within its financial landscape.
Read more →TEVAThe following tables present revenues, expenses and profit for each segment for the years ended
Teva Pharmaceuticals has reported its revenues, expenses, and profits for 2023 across its various segments. The United States segment showed a notable revenue increase to $7,731 million with a corresponding rise in segment profit. However, R&D expenses have also increased, which could affect future profitability. The International Markets segment experienced a decline in profit compared to the previous year, indicating challenges in that area.
Read more →TEVATeva Reports Growth in Fourth Quarter and Full Year 2023 2023 revenues of $15.8 billion reflect an increase of 7% in local currency terms, compared to 2022 AUSTEDO - exceeding $1.2 billion in annual revenues, up 28% from
Teva Pharmaceutical Industries Ltd. reported positive financial results for the fourth quarter and full year of 2023, with total revenues of $15.8 billion, reflecting a 7% increase in local currency. Notably, AUSTEDO surpassed $1.2 billion in annual revenues, growing 28% year-over-year. However, the company disclosed errors in its financial statements, resulting in a revision of previously reported figures and the identification of a material weakness in internal controls. Despite these issues, Teva anticipates sustained growth in its key brands and generics business moving forward.
Read more →TEVATeva Reports Third Quarter 2023 Financial Results and Increases Revenue Guidance 2023 revenues outlook revised to $15.1 - $15.5 billion from $15.0 - $15.4 billion Global revenues of $3.9 billion, reflect an increase of 7
Teva Pharmaceutical Industries Ltd. reported strong financial results for Q3 2023, with revenues increasing by 7% year-over-year to $3.9 billion. The company has raised its revenue guidance for the year to a range of $15.1 to $15.5 billion, signaling confidence in its growth strategy amidst ongoing challenges due to geopolitical events. Teva's recent collaborations and innovations in its late-stage pipeline are also notable. However, the company's operating income declined compared to the previous year due to rising costs in R&D and legal settlements, alongside negative impacts from exchange rate fluctuations.
Read more →TEVASanofi and Teva announce exclusive collaboration to deliver inflammatory bowel disease treatment TEV 574, a novel anti-TL1A therapy, is being developed to treat ulcerative colitis and Crohn s disease Collab
Sanofi and Teva have entered an exclusive collaboration to co-develop TEV 574, an anti-TL1A therapy aimed at treating ulcerative colitis and Crohn's disease. TEV 574 is currently in Phase 2b clinical trials and holds potential as a best-in-class option in the inflammatory bowel disease sector. Under the agreement, Teva will gain significant upfront payments and share development costs with Sanofi, which will lead commercialization in North America and other regions. Initial results from the program are anticipated to be available in 2024, although regulatory approvals could present uncertainties.
Read more →TEVATEVA ANNOUNCES CHANGES TO EXECUTIVE MANAGEMENT TEAM TEL AVIV, Israel & PARSIPPANY, N.J.
Teva Pharmaceutical Industries Ltd. has announced changes to its executive management team, with Christine Fox set to join as the new head of U.S. Commercial Business. Fox, who previously served as Global President at Novartis Gene Therapies, has extensive healthcare experience spanning over 30 years. She replaces Sven Dethlefs, who will be leaving the company on November 17, 2023. Teva's contributions to the pharmaceutical sector and its position in the market are highlighted in the announcement.
Read more →TEVATEVA SETTLES PRICE FIXING CHARGES WITH U.S. DOJ TEL AVIV, Israel & PARSIPPANY, N.J
Teva Pharmaceuticals has reached a deferred prosecution agreement with the U.S. DOJ to settle criminal price-fixing charges initiated in 2020. The settlement includes a $225 million fine, spread over five years, and a commitment to donate $50 million in generic products to humanitarian organizations. Teva acknowledges that a former employee's actions contributed to the case and is taking steps to enhance compliance measures. This agreement allows the company to move forward without being excluded from federal health care programs.
Read more →TEVA▲ +11.6%on this news
Teva Reports Second Quarter 2023 Financial Results Revenues of $3.9 billion GAAP loss per share of $0.77 Non-GAAP diluted EPS of $0.56 Cash flow generated from operating activities of $324 million Free cash flow of $632
Teva Pharmaceutical Industries reported its financial results for the second quarter of 2023, showing revenues of $3.9 billion, reflecting a 4% increase in local currency terms. The company continues to pursue its Pivot to Growth strategy, focusing on product innovation and operational efficiencies. However, Teva experienced a net loss of $863 million, which was higher than the previous year's loss. While revenue guidance was slightly increased, rising costs due to inflation contributed to decreased gross profit margins.
Read more →TEVATEVA CONCLUDES NATIONWIDE OPIOIDS SETTLEMENT AGREEMENT Settles with all 50 states and 99 percent of litigating subdivisions Shipments of life-saving generic Narcan (naloxone hydrochloride nasal spray) have already begun;
Teva Pharmaceuticals has reached a nationwide settlement agreement concluding opioid litigation with all 50 states and 99% of litigating subdivisions, resolving its case with Nevada specifically. The company agreed to pay Nevada $193 million over 20 years. Teva has begun shipments of its generic Narcan and expects to expand these efforts under the settlement in 2024. However, the agreement does not admit wrongdoing and does not resolve all claims against Teva, leaving potential risks in ongoing legal disputes.
Read more →TEVA▼ -8.2%on this news
Teva Reports First Quarter 2023 Financial Results and Reaffirms 2023 Non-GAAP Outlook TEL AVIV, Israel--(BUSINESS WIRE)
Teva Pharmaceutical Industries Ltd. reported first quarter 2023 financial results, revealing revenues of $3.7 billion, a 4% increase in local currency. The company affirmed its 2023 non-GAAP outlook, which is bolstered by strong performances from innovative brands like AUSTEDO and AJOVY. However, challenges remain, including a 9% decrease in gross profit and negative impacts from exchange rate movements. Moving forward, Teva's new strategy aims to create long-term value and address current headwinds.
Read more →TEVATeva Announces Successful Upsize and Pricing of $2,490,000,000 (equivalent) Sustainability-Linked Senior Notes and the Increase of the Maximum Tender Amount of its Debt Tender Offer Proceeds to Repay Existing Debt TEL AV
Teva Pharmaceutical Industries Ltd. has successfully upsized its offering of sustainability-linked senior notes to approximately $2.49 billion, up from $2.06 billion. The company has also increased the maximum tender amount for its debt tender offer from $2.25 billion to $2.5 billion, indicating strong demand. The proceeds will be used for purchasing outstanding senior notes and for repaying existing debt. This marks Teva's second issuance of sustainability-linked senior notes, reaffirming its commitment to sustainable finance and environmental initiatives.
Read more →TEVA▼ -8.9%on this news
Teva Reports Fourth Quarter and Full Year 2022 Financial Results TEL AVIV, Israel--(BUSINESS WIRE)
Teva Pharmaceutical Industries Ltd. has announced its fourth quarter and full year 2022 financial results, showcasing both challenges and growth initiatives. The company reported a total revenue of $14.9 billion, which is a 6% decrease from 2021, primarily due to a decline in sales from some key products. Despite a net loss attributable to Teva of $2.35 billion for the year, the new CEO highlighted positive performances in innovative brands and cash flow generation. Teva aims to continue optimizing its operations and addressing market needs in the coming year.
Read more →TEVATeva Announces Appointment of Richard Francis as President and CEO K re Schultz to Retire After a Transformative Five-Year Tenure Setting the Stage for an Exciting Future
Teva Announces Appointment of Richard Francis as President and CEO K re Schultz to Retire After a Transformative Five-Year Tenure Setting the Stage for an Exciting Future TEL AVIV, Israel November 21, 2022 Teva Pharmaceutical Industries Ltd. ( Teva or the Company ) (NYSE and TA
Read more →TEVATeva Reports Third Quarter 2022 Financial Results Key financial highlights and outlook Revenues of $3.6 billion GAAP diluted EPS of $0.05 Non-GAAP diluted EPS of $0.59 Cash flow generated from operating activities of $54
Teva Reports Third Quarter 2022 Financial Results Key financial highlights and outlook TEL AVIV, Israel--(BUSINESS WIRE)--November 3, 2022--Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today reported results for the quarter ended September 30, 2022. Mr. K re Schul
Read more →TEVATeva Reports Second Quarter 2022 Financial Results Teva has reached agreement in principle on the primary financial terms of a nationwide opioids settlement and has revised its provision to reflect its terms Key financia
Teva Reports Second Quarter 2022 Financial Results Teva has reached agreement in principle on the primary financial terms of a nationwide opioids settlement and has revised its provision to reflect its terms Key financial highlights and outlook TEL AVIV, Israel--(BUSINESS WIRE
Read more →TEVATeva Reports First Quarter 2022 Financial Results Revenues of $3.7 billion GAAP diluted loss per share of $0.86 Non-GAAP diluted EPS of $0.55 Cash flow used in operating activities of $49 million Free cash flow of $117 m
Teva Reports First Quarter 2022 Financial Results TEL AVIV, Israel--(BUSINESS WIRE)--May 3, 2022--Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today reported results for the quarter ended March 31, 2022. Mr. K re Schultz, Teva's President and CEO, said, 2022 is off
Read more →TEVA▲ +8.4%on this news
Teva Reports Fourth Quarter and Full Year 2021 Financial Results TEL AVIV, Israel--(BUSINESS WIRE)
Teva Reports Fourth Quarter and Full Year 2021 Financial Results TEL AVIV, Israel--(BUSINESS WIRE)--February 9, 2022--Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today reported results for the year and the quarter ended December 31, 2021. "In 2021 Teva delivered s
Read more →TEVA▲ +9.5%on this news
Teva Announces Successful Upsize of Sustainability-Linked Senior Notes Offering and Pricing of $5,000,000,000 of Sustainability-Linked Senior Notes Proceeds to Repay Existing Debt TEL AVIV (BUSINESS WIRE)
Teva Announces Successful Upsize of Sustainability-Linked Senior Notes Offering and Pricing of $5,000,000,000 of Sustainability-Linked Senior Notes Proceeds to Repay Existing Debt TEL AVIV (BUSINESS WIRE) November 2, 2021 Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA
Read more →TEVATeva Reports Third Quarter 2021 Financial Results Revenues of $3.9 billion GAAP diluted EPS of $0.26 Non-GAAP diluted EPS of $0.59 Cash flow generated from operating activities of $529 million Free cash flow of $795 mill
Teva Reports Third Quarter 2021 Financial Results TEL AVIV, Israel--(BUSINESS WIRE)--October 27, 2021--Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today reported results for the quarter ended September 30, 2021. Mr. K re Schultz, Teva's President and CEO, said, "I
Read more →TEVA▲ +12%on this news
Teva Reports Second Quarter 2021 Financial Results Revenues of $3.9 billion GAAP diluted EPS of $0.19 Non-GAAP diluted EPS of $0.59 Cash flow generated from operating activities of $218 million Free cash flow of $625 mil
Teva Reports Second Quarter 2021 Financial Results TEL AVIV, Israel--(BUSINESS WIRE)--July 28, 2021--Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today reported results for the quarter ended June 30, 2021. Mr. K re Schultz, Teva's President and CEO, said, "We have
Read more →TEVATeva Announces Changes to Executive Management Team TEL AVIV, Israel & PARSIPPANY, N.J.--(BUSINESS WIRE)
Teva Announces Changes to Executive Management Team TEL AVIV, Israel & PARSIPPANY, N.J.--(BUSINESS WIRE)--July 21, 2021--Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced changes to its leadership team. Brendan O'Grady, Executive Vice President, North Ame
Read more →TEVATeva Reports First Quarter 2021 Financial Results Revenues of $4.0 billion GAAP diluted EPS of $0.07 Non-GAAP diluted EPS of $0.63 Cash flow used in operating activities of $405 million Free cash flow of $59 million Full
Teva Reports First Quarter 2021 Financial Results TEL AVIV, Israel--(BUSINESS WIRE)--April 28, 2021--Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today reported results for the quarter ended March 31, 2021. Mr. K re Schultz, Teva's President and CEO, said, "As the
Read more →TEVATeva Reports Fourth Quarter and Full Year 2020 Financial Results TEL AVIV, Israel--(BUSINESS WIRE)
Teva Reports Fourth Quarter and Full Year 2020 Financial Results TEL AVIV, Israel--(BUSINESS WIRE)--February 10, 2021--Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today reported results for the year and the quarter ended December 31, 2020. "In 2020, Teva continued
Read more →TEVATeva Reports Third Quarter 2020 Financial Results Revenues of $4.0 billion GAAP diluted loss per share of $3.97 Non-GAAP diluted EPS of $0.58 Free cash flow of $506 million Full year 2020 business outlook revised: Net re
Teva Reports Third Quarter 2020 Financial Results TEL AVIV, Israel--(BUSINESS WIRE)--November 5, 2020--Teva Pharmaceutical Industries Ltd. (NYSE: TEVA, TASE: TEVA) today reported results for the quarter ended September 30, 2020. Mr. K re Schultz, Teva's President and CEO, said,
Read more →TEVATeva Reports Second Quarter 2020 Financial Results Revenues of $3.9 billion GAAP diluted EPS of $0.13 Non-GAAP diluted EPS of $0.55 Free cash flow of $582 million Full year 2020 business outlook reaffirmed: Net revenues
Teva Reports Second Quarter 2020 Financial Results TEL AVIV, Israel--(BUSINESS WIRE)--August 5, 2020--Teva Pharmaceutical Industries Ltd. (NYSE: TEVA, TASE: TEVA) today reported results for the quarter ended June 30, 2020. Mr. K re Schultz, Teva's President and CEO, said, "As t
Read more →TEVATeva Reports First Quarter 2020 Financial Results Revenues of $4.4 billion GAAP diluted EPS of $0.06 Non-GAAP diluted EPS of $0.76 Free cash flow of $551 million Full year 2020 business outlook reaffirmed: Net revenues o
Teva Reports First Quarter 2020 Financial Results TEL AVIV, Israel--(BUSINESS WIRE)--May 7, 2020--Teva Pharmaceutical Industries Ltd. (NYSE: TEVA, TASE: TEVA) today reported results for the quarter ended March 31, 2020. Mr. K re Schultz, Teva's President and CEO, said, "2020 br
Read more →TEVATeva Reports Fourth Quarter and Full Year 2019 Financial Results TEL AVIV, Israel--(BUSINESS WIRE)
Teva Reports Fourth Quarter and Full Year 2019 Financial Results TEL AVIV, Israel--(BUSINESS WIRE)--February 12, 2020--Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today reported results for the year and the quarter ended December 31, 2019. "In 2019, we made great
Read more →TEVATeva Announces Appointment of New Chief Financial Officer JERUSALEM--(BUSINESS WIRE)
Teva Announces Appointment of New Chief Financial Officer JERUSALEM--(BUSINESS WIRE)--November 7, 2019--Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) announced today the appointment of Eli Kalif as Executive Vice President and Chief Financial Officer. Mr. Kalif will
Read more →TEVATeva Reports Third Quarter 2019 Financial Results Revenues of $4.3 billion GAAP diluted loss per share of $0.29 Non-GAAP diluted EPS of $0.58 Free cash flow of $551 million Spend base reduction of $2.9 billion since init
Teva Reports Third Quarter 2019 Financial Results JERUSALEM--(BUSINESS WIRE)--November 7, 2019--Teva Pharmaceutical Industries Ltd. (NYSE: TEVA, TASE: TEVA) today reported results for the quarter ended September 30, 2019. Mr. K re Schultz, Teva's President and CEO, said, "Durin
Read more →TEVATeva Settles Track 1 Opioid Cases and Reaches Agreement on Framework to Settle Remaining Litigation PARSIPPANY, N.J. & JERUSALEM--(BUSINESS WIRE)
Teva Settles Track 1 Opioid Cases and Reaches Agreement on Framework to Settle Remaining Litigation PARSIPPANY, N.J. & JERUSALEM--(BUSINESS WIRE)--October 21, 2019--Teva Pharmaceutical Industries Ltd. and its affiliates today announced a settlement agreement with both Cuyahoga a
Read more →TEVATeva Reports Second Quarter 2019 Financial Results Revenues of $4.3 billion GAAP diluted loss per share of $0.63 Non-GAAP diluted EPS of $0.60 Spend base reduction of $2.7 billion since initiation of the restructuring pl
Teva Reports Second Quarter 2019 Financial Results JERUSALEM--(BUSINESS WIRE)--August 7, 2019--Teva Pharmaceutical Industries Ltd. (NYSE: TEVA, TASE: TEVA) today reported results for the quarter ended June 30, 2019. Mr. K re Schultz, Teva's President and CEO, said, "During the
Read more →TEVATeva Reports First Quarter 2019 Financial Results Revenues of $4.3 billion GAAP diluted loss per share of $0.10 Non-GAAP diluted EPS of $0.60 Free cash flow of $360 million Spend base reduction of $2.5 billion since init
Teva Reports First Quarter 2019 Financial Results JERUSALEM--(BUSINESS WIRE)--May 2, 2019--Teva Pharmaceutical Industries Ltd. (NYSE: TEVA, TASE: TEVA) today reported results for the quarter ended March 31, 2019. Mr. K re Schultz, Teva's President and CEO, said, "The second yea
Read more →TEVATeva Reports Fourth Quarter and Full Year 2018 Financial Results JERUSALEM--(BUSINESS WIRE)
Teva Reports Fourth Quarter and Full Year 2018 Financial Results JERUSALEM--(BUSINESS WIRE)--February 13, 2019--Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today reported results for the year and the quarter ended December 31, 2018. 2019 Business outlook: Mr. K r
Read more →TEVATeva Reports Third Quarter 2018 Financial Results Revenues of $4.5 billion Free cash flow of $704 million GAAP diluted loss per share of $0.27 Non-GAAP diluted EPS of $0.68 Spend base reduction of $1.8 billion in the fir
Teva Reports Third Quarter 2018 Financial Results JERUSALEM--(BUSINESS WIRE)--November 1, 2018--Teva Pharmaceutical Industries Ltd. (NYSE: TEVA, TASE: TEVA) today reported results for the quarter ended September 30, 2018. Mr. K re Schultz, Teva's President and CEO, said, "I am
Read more →TEVATeva Reports Second Quarter 2018 Financial Results Revenues of $4.7 billion Free cash flow of $0.6 billion GAAP diluted loss per share of $0.24 Non-GAAP diluted EPS of $0.78 Restructuring plan on-track to achieve $1.5 bi
Teva Reports Second Quarter 2018 Financial Results JERUSALEM--(BUSINESS WIRE)--August 2, 2018--Teva Pharmaceutical Industries Ltd. (NYSE: TEVA, TASE: TEVA) today reported results for the quarter ended June 30, 2018. Mr. K re Schultz, Teva's President and CEO, said, "I am satisf
Read more →TEVATeva Reports First Quarter 2018 Financial Results Revenues of $5.1 billion Free cash flow of $1.9 billion GAAP EPS of $1.03 Non-GAAP EPS of $0.94 Restructuring plan on-track to achieve $1.5 billion of savings in 2018 and
Teva Reports First Quarter 2018 Financial Results JERUSALEM--(BUSINESS WIRE)--May 3, 2018--Teva Pharmaceutical Industries Ltd. (NYSE: TEVA, TASE: TEVA) today reported results for the quarter ended March 31, 2018. Mr. K re Schultz, Teva's President and CEO, said "2018 is off to
Read more →TEVASelected financial data by segment (unaudited) North America Segment Year ended December 31, Three months ended 2017 2016 December 31, September 30, June 30
Selected financial data by segment (unaudited) North America Segment Year ended December 31, Three months ended 2017 2016 December 31, September 30, June 30, March 31, 2017 (Unaudited, U.S.$ in millions) Revenues $ 12,141 $ 11,778 $ 2,689
Read more →TEVATeva Reports 2017 Full Year and Fourth Quarter Financial Results JERUSALEM--(BUSINESS WIRE)
Teva Reports 2017 Full Year and Fourth Quarter Financial Results JERUSALEM--(BUSINESS WIRE)--February 8, 2018--Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) today reported results for the year and the quarter ended December 31, 2017. 2018 Business outlook: K re Schultz, Teva
Read more →TEVATEVA COMPLETES AMENDMENT TO CREDIT FACILITIES Jerusalem, Feb. 1 , 2018 Teva Pharmaceutical Industries Ltd., (NYSE and TASE: TEVA) today announced amendments to its USD and JPY term loan and revolving credit facilities, p
TEVA COMPLETES AMENDMENT TO CREDIT FACILITIES Jerusalem, Feb. 1 , 2018 Teva Pharmaceutical Industries Ltd., (NYSE and TASE: TEVA) today announced amendments to its USD and JPY term loan and revolving credit facilities, providing the company greater flexibility in its financial l
Read more →TEVAWEBCAST ALERT FOR IMMEDIATE RELEASE Teva to Present at the 36 th Annual J.P. Morgan Healthcare Conference Jerusalem
WEBCAST ALERT FOR IMMEDIATE RELEASE Teva to Present at the 36 th Annual J.P. Morgan Healthcare Conference Jerusalem, January 4, 2018 Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) will host a live audio webcast at the 36 th Annual J.P. Morgan Healthcare Conference. K re Schul
Read more →TEVATEVA ANNOUNCES LAUNCH OF AN AUTHORIZED GENERIC OF ESTRACE CREAM IN THE UNITED STATES Jerusalem
TEVA ANNOUNCES LAUNCH OF AN AUTHORIZED GENERIC OF ESTRACE CREAM IN THE UNITED STATES Jerusalem, January 2, 2018 Teva Pharmaceutical Industries Ltd., (NYSE and TASE: TEVA) today announced the launch of an authorized generic of Estrace 1 Cream (estradiol vaginal cream, USP, 0.01%
Read more →TEVATEVA ANNOUNCES RESTRUCTURING PLAN AND ADDITIONAL MEASURES TO IMPROVE ITS BUSINESS AND FINANCIAL PERFORMANCE Total cost base to be reduced by $3 billion by the end of 2019 Workforce to be reduced by over 25% Dividend susp
TEVA ANNOUNCES RESTRUCTURING PLAN AND ADDITIONAL MEASURES TO IMPROVE ITS BUSINESS AND FINANCIAL PERFORMANCE Jerusalem, December 14, 2017 Teva Pharmaceutical Industries Ltd. (NYSE & TASE: TEVA) announced today a comprehensive restructuring plan to significantly reduce its cost b
Read more →TEVATeva Reports Third Quarter 2017 Financial Results Revenues of $5.6 billion Cash flow from operations of $1.1 billion GAAP EPS of $0.52 Non-GAAP EPS of $1.00 Teva announces third quarter 2017 dividend of 8.5 cents 2017 ou
Teva Reports Third Quarter 2017 Financial Results JERUSALEM--(BUSINESS WIRE)--November 2, 2017--Teva Pharmaceutical Industries Ltd. (NYSE: TEVA, TASE: TEVA) today reported results for the quarter ended September 30, 2017. Revenues in the third quarter of 2017 were $5.6 billion,
Read more →TEVAExecution Version AMENDMENT TO SENIOR UNSECURED REVOLVING CREDIT AGREEMENT This AMENDMENT to the Senior Unsecured Revolving Credit Agreement, dated as of
Execution Version AMENDMENT TO SENIOR UNSECURED REVOLVING CREDIT AGREEMENT This AMENDMENT to the Senior Unsecured Revolving Credit Agreement, dated as of September 18, 2017 (this Amendment ), is made and entered into by and among TEVA PHARMACEUTICAL INDUSTRIES LIMITED, an Israe
Read more →TEVATeva Reports Second Quarter 2017 Financial Results Revenues of $5.7 billion GAAP EPS loss of $5.94 Non-GAAP EPS of $1.02 2017 business outlook revised to non-GAAP EPS of $4.30 - $4.50 Teva announces second quarter 2017 d
Teva Reports Second Quarter 2017 Financial Results JERUSALEM--(BUSINESS WIRE)--August 3, 2017--Teva Pharmaceutical Industries Ltd. (NYSE: TEVA, TASE: TEVA) today reported results for the quarter ended June 30, 2017. "Second quarter results were lower than we anticipated due to
Read more →TEVACelltrion and Teva Announce U.S. FDA Acceptance of Biologics License Application for Proposed Biosimilar to Herceptin (trastuzumab) INCHEON, Republic of Korea & JERUSALEM--(BUSINESS WIRE)
Celltrion and Teva Announce U.S. FDA Acceptance of Biologics License Application for Proposed Biosimilar to Herceptin (trastuzumab) INCHEON, Republic of Korea & JERUSALEM--(BUSINESS WIRE)--July 31, 2017--Celltrion, Inc. and Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEV
Read more →Competitive Position
How TEVA ranks across every disease it competes inCompetitive Position is a premium feature
See how TEVA ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial